Cancers 2011, 3(1), 1372-1382; doi:10.3390/cancers3011372
Review

The Potential Use of N-Myristoyltransferase as a Biomarker in the Early Diagnosis of Colon Cancer

1 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan S7N OW8, Canada 2 Cancer Research Unit, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada 3 Drug Design and Discovery Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada
* Author to whom correspondence should be addressed.
Received: 6 February 2011; in revised form: 9 March 2011 / Accepted: 11 March 2011 / Published: 16 March 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
PDF Full-text Download PDF Full-Text [511 KB, uploaded 16 March 2011 10:11 CET]
Abstract: Colon cancer is one of the most common malignant diseases and a major cause of mortality in the Western world. Metastasis to lymph nodes and other gastrointestinal organs, especially to the liver and lungs, is most common and occurs in up to 25% of cancer patients when initially diagnosed. The majority of colon cancers develop from noncancerous adenomatous polyps on the lining of the colon which grow over the years to become cancerous. If detected early, the surgical resections of the growth, often in combination with chemotherapy, significantly increases life expectancy. We have shown that the enzyme N-myristoyltransferase (NMT) which carries out lipid modification of several proteins (including many of those involved in oncogenesis) is expressed at higher levels in cancerous tissues from the colon. We have also shown that in peripheral blood mononuclear cells (PBMC) and bone marrow (BM) cells collected from colon cancer patients and from azoxymethane-induced rats the expression and localization of NMT is altered. We have observed strong positivity for NMT in immunohistochemical analysis for PBMC from colon cancer patients as compared to control groups. Furthermore, in the bone marrow (BM) mononuclear cells, NMT was found to be confined to the nuclei whereas in control groups it was observed to be located in the cytoplasm. In conclusion, this strikingly differential localization offers the basis of a potential investigational tool for screening or diagnosis of individuals at risk for or suspected of having colon cancer.
Keywords: colon cancer; human adenocarcinoma; N-myristoyltransferase; protein myristoylation

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Kumar, S.; Dimmock, J.R.; Sharma, R.K. The Potential Use of N-Myristoyltransferase as a Biomarker in the Early Diagnosis of Colon Cancer. Cancers 2011, 3, 1372-1382.

AMA Style

Kumar S, Dimmock JR, Sharma RK. The Potential Use of N-Myristoyltransferase as a Biomarker in the Early Diagnosis of Colon Cancer. Cancers. 2011; 3(1):1372-1382.

Chicago/Turabian Style

Kumar, Sujeet; Dimmock, Jonathan R; Sharma, Rajendra K. 2011. "The Potential Use of N-Myristoyltransferase as a Biomarker in the Early Diagnosis of Colon Cancer." Cancers 3, no. 1: 1372-1382.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert